Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study

David L. Grinblatt, Gail J. Roboz, Daniel A. Pollyea, Mikkael A. Sekeres, Bart L. Scott, Karen Seiter, Amer M. Zeidan, Jay L. Patel, Guillermo Garcia-Manero, Rami S. Komrokji, Michael R. Savona, Irene S. Degutis, Pavel Kiselev, Edward Yu, Willem Heydendael, Ying Qiu, Sara Vergara, Ali McBride, Harry P. Erba

Blood (2023) 142 (Supplement 1): 593.

https://doi.org/10.1182/blood-2023-189963

Published: 2023

Journal Articles

Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes

Mikkael A. Sekeres, Guillermo Garcia-Manero, David L. Grinblatt, Rami S. Komrokji, Michael R. Savona, Harry P. Erba, Gail J. Roboz, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Adeola Y. Makinde, Ali McBride, Bart L. Scott

Blood (2022) 140 (Supplement 1): 9818–9820.

https://doi.org/10.1182/blood-2022-158075

Published: 2022

Journal Articles

Treatment Patterns and Outcomes of Patients with Primary or Secondary Acute Myeloid Leukemia By Type of Site (Academic or Community/Government): A CONNECT® Myeloid Registry Study

Bart L. Scott, Michael R. Savona, Gail J. Roboz, Karen Seiter, Daniel A. Pollyea, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Ali McBride, Willem Heydendael, Harry P. Erba

Blood (2022) 140 (Supplement 1): 8923–8925.

https://doi.org/10.1182/blood-2022-158068

Published: 2022

Journal Articles

Treatment Patterns and Outcomes of Patients with NPM1 + Acute Myeloid Leukemia (AML) Enrolled in the CONNECT® Myeloid Disease Registry

Daniel A. Pollyea, Jaroslaw P. Maciejewski, Gail J. Roboz, Karen Seiter, Bart L. Scott, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Ali McBride, Willem Heydendael, Harry P. Erba

Blood (2022) 140 (Supplement 1): 11844–11846.

https://doi.org/10.1182/blood-2022-156679

Published: 2022

Journal Articles

Treatment Patterns and Survival Outcomes of Patients with Acute Myeloid Leukemia Who Achieved Remission in the Connect ® Myeloid Disease Registry

Gail J. Roboz, Mehrdad Abedi, Michael A. Thompson, Mikkael A. Sekeres, Daniel A. Pollyea, Karen Seiter, Edward Yu, Pavel Kiselev, Michelle Little, Irina Fernandez, Irene S. DeGutis, Harry P. Erba

Blood (2021) 138 (Supplement 1): 279.

https://doi.org/10.1182/blood-2021-145849

Published: 2021

Journal Articles

Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect ® Myeloid Disease Registry

Rami S. Komrokji, Tracy I. George, Harry P. Erba, Bart L. Scott, David L. Grinblatt, Jaroslaw P. Maciejewski, Gail J. Roboz, Michael R. Savona, Guillermo Garcia-Manero, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Adeola Y. Makinde, Mikkael A. Sekeres

Blood (2021) 138 (Supplement 1): 3686.

https://doi.org/10.1182/blood-2021-145853

Published: 2021

Journal Articles

Connect ® Lymphoma Disease Registry: A US-Based, Prospective, Observational Cohort Study

Christopher R. Flowers, David Andorsky, John M. Burke, James R. Cerhan, David L. Grinblatt, Chris L. Pashos, Kathleen Toomey, Andrew D. Zelenetz, Kristen Sullivan, E. Dawn Flick, Pavel Kiselev, Mark Kaplan, Jung Ryun Ahn

Blood (2021) 138 (Supplement 1): 1460.

https://doi.org/10.1182/blood-2021-145135

Published: 2021

Journal Articles

Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect ® MDS/AML Disease Registry

Gail J. Roboz, MD, Christopher R. Cogle, Daniel A. Pollyea, Mehrdad Abedi, MD, Michael A. Thompson, MD PhD, Melissa Nifenecker, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Michelle Little, Harry P. Erba

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-135877

Published: 2020

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Disease Registry

Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami S. Komrokji, MD, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, Chrystal U. Louis, E. Dawn Flick, Melissa Nifenecker, Pavel Kiselev, Arlene S. Swern, David P. Steensma

Blood (2018) 132 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2018-99-111145

Published: 2018

Journal Articles

Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect ® MDS/AML Disease Registry

Sudipto Mukherjee, MD PhD MPH, Mehrdad Abedi, MD, Harry P. Erba, MD PhD, Daniel A Pollyea, MD, Gail J. Roboz, MD, Michael A. Thompson, MD PhD FASCO, Chrystal U. Louis, E. Dawn Flick, Melissa Nifenecker, Pavel Kiselev, Arlene S. Swern, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 4736.

https://doi.org/10.1182/blood-2018-99-112935

Published: 2018

Journal Articles

Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients

Blood (2016) 128 (22): 3222.

https://doi.org/10.1182/blood.V128.22.3222.3222

Published: 2016

Journal Articles

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Inhye E Ahn, MD, Charles Michael Farber, MD PhD, Matthew Davids, MD, David L. Grinblatt, MD, Nicole Lamanna, MD, Anthony R. Mato, MDMSCE, Chadi Nabhan, MD MBA, FACP, Pavel Kiselev, PhD, Arlene S. Swern, PhD, E. Dawn Flick, RPh, MPH, ScD, Shriya Bhushan, PharmD, Kristen Sullivan, MBA, CCRA, Jeff Sharman, MD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 3581.

https://doi.org/10.1182/blood.V128.22.3581.3581

Published: 2016

Journal Articles

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ® Myelodysplastic Syndromes (MDS) and AML Disease Registry

Blood (2016) 128 (22): 3548.

https://doi.org/10.1182/blood.V128.22.3548.3548

Published: 2016

Journal Articles

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Jeff Sharman, MD, Matthew Davids, MD, Charles Michael Farber, MD PhD, David L. Grinblatt, MD, Neil E. Kay, MD, Nicole Lamanna, MD, Anthony R. Mato, MD, Chadi Nabhan, MD MBA, FACP, Kristen Sullivan, MBA, CCRA, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 5941.

https://doi.org/10.1182/blood.V128.22.5941.5941

Published: 2016

Journal Articles

Undertreatment of Patients (Pts) with Myelodysplastic Syndromes (MDS): Analysis of a Large Electronic Medical Records (EMR) Database Cohort of US Pts with MDS

David P. Steensma, MD, Bart L Scott, MD, Xiaomei Ma, PhD, Albert Fliss, PhD, Pavel Kiselev, PhD, Arlene S. Swern, PhD, Mary M. Sugrue, MD PhD

Blood (2016) 128 (22): 4768.

https://doi.org/10.1182/blood.V128.22.4768.4768

Published: 2016

Journal Articles

Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients

Blood (2016) 128 (22): 4400.

https://doi.org/10.1182/blood.V128.22.4400.4400

Published: 2016

Journal Articles

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Blood (2016) 128 (18): 2199–2205.

https://doi.org/10.1182/blood-2016-05-716977

Published: 2016

Includes: Supplemental data

Journal Articles

Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry

Charles M. Farber, MD, Anthony Mato, MD, Chadi Nabhan, MD, Thomas J. Kipps, MD, PhD, Christopher Flowers, MD, Neil E. Kay, MD, Nicole Lamanna, MD, David L. Grinblatt, MD, Mark Kozloff, MD, Mark Weiss, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 5270.

https://doi.org/10.1182/blood.V126.23.5270.5270

Published: 2015

Journal Articles

Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Anthony Mato, MD, Chadi Nabhan, MD, Christopher Flowers, MD, Neil E. Kay, MD, Thomas J. Kipps, MD, PhD, David L. Grinblatt, MD, Nicole Lamanna, MD, Mark Kozloff, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 4483.

https://doi.org/10.1182/blood.V126.23.4483.4483

Published: 2015

NARROW

Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study

Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes

Treatment Patterns and Outcomes of Patients with Primary or Secondary Acute Myeloid Leukemia By Type of Site (Academic or Community/Government): A CONNECT® Myeloid Registry Study

Treatment Patterns and Outcomes of Patients with NPM1 + Acute Myeloid Leukemia (AML) Enrolled in the CONNECT® Myeloid Disease Registry

Treatment Patterns and Survival Outcomes of Patients with Acute Myeloid Leukemia Who Achieved Remission in the Connect ® Myeloid Disease Registry

Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect ® Myeloid Disease Registry

Connect ® Lymphoma Disease Registry: A US-Based, Prospective, Observational Cohort Study

Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect ® MDS/AML Disease Registry

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Disease Registry

Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect ® MDS/AML Disease Registry

Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ® Myelodysplastic Syndromes (MDS) and AML Disease Registry

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Undertreatment of Patients (Pts) with Myelodysplastic Syndromes (MDS): Analysis of a Large Electronic Medical Records (EMR) Database Cohort of US Pts with MDS

Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry

Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only